TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

By sjmartinez • October 29, 2024

Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, Danchaivijitr P, Han JY, Sun JM, Sugawara S, Pan E, Ren N, Chen A, Rajagopalan R, Lisberg AE. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol. 2024 Oct 29:1-10. doi: 10.1080/14796694.2024.2409621. Epub ahead of print. PMID: 39469838.

Tags: Antibody–drug conjugate, Dato-DXd, Datopotamab deruxtecan, Hematology/Oncology, non-small-cell lung cancer, Publications, TROPION

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Armand P, Zinzani PL, Timmerman JM, Johnson NA, Lavie D, Thiagarajan K, Topp B, Pillai PM, Herrera AF. Estimating efficacy of favezelimab plus pembrolizumab relative[...]

Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair

Hollowed J, Woo H, Hamburg S, Ardehali A. Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair. Tex Heart Inst J. 2025 Jul[...]

Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease

Fine SA, Lim SY, Siena NM, de Jesus AB, Goh T, Markus L, Russell TA, Kendal JK, Lofftus SY, Shehata MS, Dao HB, Lee A,[...]